Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Deutsche Bank AG

Deutsche Bank AG increased its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,012 shares of the specialty pharmaceutical company’s stock after acquiring an additional 609 shares during the period. Deutsche Bank AG’s holdings in Jazz Pharmaceuticals were worth $1,972,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Moloney Securities Asset Management LLC purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth about $464,000. BTC Capital Management Inc. grew its position in shares of Jazz Pharmaceuticals by 9.4% during the fourth quarter. BTC Capital Management Inc. now owns 49,653 shares of the specialty pharmaceutical company’s stock worth $6,115,000 after acquiring an additional 4,271 shares during the last quarter. Summit Trail Advisors LLC acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $539,000. Atria Investments Inc raised its stake in Jazz Pharmaceuticals by 19.5% during the 4th quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company’s stock valued at $336,000 after acquiring an additional 445 shares in the last quarter. Finally, Pacer Advisors Inc. grew its position in Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock valued at $272,713,000 after buying an additional 115,102 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Up 0.2%

JAZZ opened at $108.07 on Friday. The firm has a market cap of $6.66 billion, a price-to-earnings ratio of 15.22, a PEG ratio of 1.04 and a beta of 0.38. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm’s 50-day simple moving average is $112.87 and its 200-day simple moving average is $121.88. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The business had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. During the same period in the prior year, the firm posted $2.68 EPS. Jazz Pharmaceuticals’s revenue for the quarter was down .5% compared to the same quarter last year. Equities research analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 4,813 shares of the business’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the sale, the chief accounting officer now directly owns 8,237 shares of the company’s stock, valued at approximately $1,189,587.54. The trade was a 36.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total transaction of $937,625.00. Following the transaction, the chief executive officer now directly owns 464,058 shares of the company’s stock, valued at $66,940,366.50. This represents a 1.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 28,236 shares of company stock worth $3,956,190 in the last quarter. 4.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on JAZZ shares. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. Barclays restated an “overweight” rating and set a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Needham & Company LLC reiterated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Wall Street Zen lowered Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 15th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $182.79.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.